Loading
TROP2 is on the surface of most breast and lung cancers. Sacituzumab govitecan and datopotamab deruxtecan are given without measuring it; a computational TROP2 score is being tested as a selector in lung cancer.
In the United States, sacituzumab govitecan (Trodelvy) is labelled for specified unresectable locally advanced or metastatic triple-negative and HR-positive/HER2-negative breast cancer settings; its urothelial indication was withdrawn on November 22, 2024. The June 24, 2026 first-line TNBC approvals cover monotherapy when PD-1/PD-L1 treatment is unsuitable, or pembrolizumab-based combination therapy when PD-L1 CPS is at least 10. Datopotamab deruxtecan (Datroway) is labelled for specified advanced HR-positive/HER2-negative breast cancer and EGFR-mutant NSCLC settings, and since May 22, 2026 for unresectable or metastatic TNBC when PD-1/PD-L1 treatment is unsuitable. These breast-cancer indications do not require a TROP2 test; the pembrolizumab combination still requires its separate PD-L1 test. The TROPION-Lung01 exploratory analysis introduced a quantitative continuous scoring (normalised membrane ratio) that separated responders in non-squamous NSCLC; it is being validated prospectively (TROPION-Lung12, NCT06564844 and other studies) and is not in any label.
In plain words · TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients.
The U.S. breast-cancer indications for sacituzumab govitecan and datopotamab deruxtecan do not require TROP2 testing. Other requirements still depend on the drug and treatment setting, including PD-L1 testing for the first-line sacituzumab-pembrolizumab combination. A computerised TROP2 score is under study in lung cancer and may become a selection test later.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate”
TRODELVY prescribing information (DailyMed)No approval uses this readout as a threshold.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares Non-small-cell lung cancer and the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/